Payment overview · 2025
General Payments
$597.89
33 reported records · 17 companies
Healthcare provider profile · identity verified
William Barton Perry, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · CENTRE, AL · NPI 1538184635
Verified facts
What the public records show
CMS Open Payments records show William Barton Perry, M.D. received $597.89 in general payments during 2025 across 33 reported records.
PFIZER INC. accounted for 23.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Jardiance, Mounjaro, Shingrix.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 209 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $140.67 | 23.5% | 9 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $82.36 | 13.8% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $62.12 | 10.4% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $50.65 | 8.5% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $49.87 | 8.3% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $21.36 | 3.6% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $20.94 | 3.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.21 | 3.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.12 | 3.4% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $18.34 | 3.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.19 | 3.0% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $17.63 | 3.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.53 | 2.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.79 | 2.6% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $15.13 | 2.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.43 | 2.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $13.55 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $597.89 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $140.67 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $140.67 | 9 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $82.36 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $50.65 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $49.87 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $42.11 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $21.36 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $18.34 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.53 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.79 | 1 | 2025 |
Source payment records
|
|||||
| Ambulatory Monitoring & Diagnostics Undivided Normalized: ambulatory monitoring diagnostics undivided |
Device | Philips North America LLC | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.43 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.43 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 13 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 57 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 69 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 16 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
16 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
57 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
209 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 536 | 126 |
| Pantoprazole Sodium | Pantoprazole Sodium | 511 | 124 |
| Losartan Potassium | Losartan Potassium | 503 | 114 |
| Gabapentin | Gabapentin | 472 | 137 |
| Levothyroxine Sodium | Levothyroxine Sodium | 420 | 88 |
| Lorazepam | Lorazepam | 372 | 84 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 369 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 322 | 65 |
| Meloxicam | Meloxicam | 311 | 71 |
| Potassium Chloride | Potassium Chloride | 307 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 307 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 286 | 79 |
| Zolpidem Tartrate | Zolpidem Tartrate | 281 | 49 |
| Metformin Hcl | Metformin Hcl | 275 | 62 |
| Furosemide | Furosemide | 255 | 70 |
| Prednisone | Prednisone | 246 | 118 |
| Alprazolam | Alprazolam | 234 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 231 | 61 |
| Tramadol Hcl | Tramadol Hcl | 223 | 45 |
| Lisinopril | Lisinopril | 217 | 55 |
| Omeprazole | Omeprazole | 215 | 61 |
| Eliquis | Apixaban | 209 | 30 |
| Simvastatin | Simvastatin | 208 | 54 |
| Pregabalin | Pregabalin | 206 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 198 | 51 |
| Montelukast Sodium | Montelukast Sodium | 193 | 43 |
| Glimepiride | Glimepiride | 188 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 184 | 38 |
| Clonazepam | Clonazepam | 182 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 171 | 34 |
| Tizanidine Hcl | Tizanidine Hcl | 160 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 154 | 57 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 152 | 36 |
| Atenolol | Atenolol | 140 | 34 |
| Doxycycline Hyclate | Doxycycline Hyclate | 133 | 103 |
| Carvedilol | Carvedilol | 129 | 37 |
| Temazepam | Temazepam | 129 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 126 | 41 |
| Allopurinol | Allopurinol | 124 | 32 |
| Escitalopram Oxalate | Escitalopram Oxalate | 121 | 21 |
| Famotidine | Famotidine | 120 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 120 | 35 |
| Sertraline Hcl | Sertraline Hcl | 113 | 26 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 110 | 30 |
| Diclofenac Sodium | Diclofenac Sodium | 107 | 26 |
| Trazodone Hcl | Trazodone Hcl | 107 | 20 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 95 | 23 |
| Alendronate Sodium | Alendronate Sodium | 94 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 94 | 23 |
| Glipizide | Glipizide | 92 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 92 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 88 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 26 |
| Propranolol Hcl | Propranolol Hcl | 80 | 15 |
| Xarelto | Rivaroxaban | 80 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 78 | 18 |
| Warfarin Sodium | Warfarin Sodium | 78 | 11 |
| Fenofibrate | Fenofibrate | 77 | 20 |
| Ozempic | Semaglutide | 75 | 16 |
| Mounjaro | Tirzepatide | 69 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 16 |
| Donepezil Hcl | Donepezil Hcl | 66 | 22 |
| Spironolactone | Spironolactone | 65 | 18 |
| Buspirone Hcl | Buspirone Hcl | 64 | 14 |
| Azithromycin | Azithromycin | 62 | 52 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 17 |
| Mirtazapine | Mirtazapine | 62 | 16 |
| Jardiance | Empagliflozin | 57 | suppressed |
| Januvia | Sitagliptin Phosphate | 55 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 54 | 28 |
| Bupropion Xl | Bupropion Hcl | 53 | suppressed |
| Cephalexin | Cephalexin | 52 | 26 |
| Methocarbamol | Methocarbamol | 52 | 12 |
| Glipizide Er | Glipizide | 51 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 51 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 50 | 12 |
| Memantine Hcl | Memantine Hcl | 48 | suppressed |
| Celecoxib | Celecoxib | 47 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 46 | suppressed |
| Dexamethasone | Dexamethasone | 45 | 41 |
| Fluconazole | Fluconazole | 45 | 25 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 45 | 15 |
| Entresto | Sacubitril/Valsartan | 44 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 43 | 41 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 43 | suppressed |
| Trulicity | Dulaglutide | 43 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | suppressed |
| Sucralfate | Sucralfate | 42 | 18 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 41 | 13 |
| Testosterone Cypionate | Testosterone Cypionate | 41 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 40 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 39 | suppressed |
| Estradiol | Estradiol | 38 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 38 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 37 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 37 | 29 |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 14 |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Diazepam | Diazepam | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Risperidone | Risperidone | 35 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 35 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 33 | suppressed |
| Amoxicillin | Amoxicillin | 32 | 29 |
| Fentanyl | Fentanyl | 31 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 14 |
| Ondansetron Odt | Ondansetron | 31 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 31 | suppressed |
| Ezetimibe | Ezetimibe | 30 | suppressed |
| Eszopiclone | Eszopiclone | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 13 |
| Valsartan | Valsartan | 29 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 27 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 26 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 25 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 25 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 24 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 24 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Calcitriol | Calcitriol | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 21 | 11 |
| Naproxen | Naproxen | 21 | suppressed |
| Acarbose | Acarbose | 20 | suppressed |
| Baclofen | Baclofen | 20 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Dutasteride | Dutasteride | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 18 |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 17 |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Bumetanide | Bumetanide | 19 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Klor-Con M10 | Potassium Chloride | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 17 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 16 | 14 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Trimethoprim | Trimethoprim | 15 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 14 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Triazolam | Triazolam | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 13 | 13 |
| Belsomra | Suvorexant | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Cefdinir | Cefdinir | 13 | 13 |
| Irbesartan | Irbesartan | 13 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Silodosin | Silodosin | 13 | suppressed |
| Dapsone | Dapsone | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Telmisartan | Telmisartan | 12 | suppressed |
| Almotriptan Malate | Almotriptan Malate | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $597.89 · 33 records | PFIZER INC. | AIRSUPRA, AREXVY, Ambulatory Monitoring & Diagnostics Undivided, BREZTRI, CAPLYTA, CAPVAXIVE, Cologuard Collection Kit, Dexcom G6 Transmitter, JARDIANCE, JATENZO, JOURNAVX, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, REPATHA, REXULTI, SHINGRIX, Veozah, XYOSTED, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error